Q BioMed Inc. announced that Dr. Helen Tager-Flusberg from Boston University has joined its advisory committee for QBM-001, which is being tested for pediatric developmental nonverbal disorder in toddlers within the autism spectrum disorders. Dr. Tager-Flusberg has provided the protocol for capturing the primary endpoint of the planned trial for QBM-001. Dr. Tager-Flusberg has dedicated much of her career to developing meaningful approaches to assess expressive language development in toddlers and children with developmental delay and autism spectrum disorders.